BiotechTube
AlgOss Biotechnologies

AlgOss Biotechnologies

Graz, Austria· Est.
algoss.at
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500K

Overview

AlgOss Biotechnologies is an Austrian private company, founded in 2016, focused on pioneering plant-derived biomaterials for bone regeneration. Its core technology platform converts marine algae into bioactive, resorbable bone graft substitutes, offering a natural alternative to synthetic or animal-derived materials. The company appears to be in a commercial or late-stage development phase, with products distributed through specialized partners in the dental and maxillofacial surgery markets. As a pioneer in its niche, AlgOss targets the growing global bone graft substitute market with a potentially superior safety and efficacy profile.

Dental & Maxillofacial SurgeryBone Regeneration

Technology Platform

Platform for converting marine algae into bioactive, resorbable bone graft substitute materials that mimic human bone structure.

Funding History

1
Total raised:$500K
Grant$500K

Opportunities

The growing global bone graft market, especially in dentistry, presents a major opportunity.
The unique plant-based, sustainable origin of its material offers a strong differentiation for marketing and could capture share from animal-derived products.
Expansion into orthopedic applications (spine, trauma) represents a significant long-term growth avenue.

Risk Factors

Key risks include slower-than-expected market adoption against established synthetic and xenograft competitors, the cost and complexity of obtaining regulatory clearance in new markets like the U.S., and potential supply chain or manufacturing challenges as a small company.
Long-term clinical data generation is also crucial.

Competitive Landscape

AlgOss competes in the crowded bone graft substitute market against major players offering synthetic (e.g., Medtronic, Stryker), bovine-derived (e.g., Geistlich), and porcine-derived materials. Its primary competitive edge is its unique plant (algae) origin, which may offer clinical and marketing advantages related to biocompatibility, resorption, and being free from animal disease concerns.

More companies in Biologics / Biosimilars →More companies in Austria →